Suppr超能文献

黑色素瘤的病理学与分子生物学

Pathology and Molecular Biology of Melanoma.

作者信息

Timis Tanase, Bergthorsson Jon Thor, Greiff Victor, Cenariu Mihai, Cenariu Diana

机构信息

Department of Oncology, Bistrita Emergency Hospital, 420094 Bistrita, Romania.

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.

出版信息

Curr Issues Mol Biol. 2023 Jun 30;45(7):5575-5597. doi: 10.3390/cimb45070352.

Abstract

Almost every death in young patients with an advanced skin tumor is caused by melanoma. Today, with the help of modern treatments, these patients survive longer or can even achieve a cure. Advanced stage melanoma is frequently related with poor prognosis and physicians still find this disease difficult to manage due to the absence of a lasting response to initial treatment regimens and the lack of randomized clinical trials in post immunotherapy/targeted molecular therapy settings. New therapeutic targets are emerging from preclinical data on the genetic profile of melanocytes and from the identification of molecular factors involved in the pathogenesis of malignant transformation. In the current paper, we present the diagnostic challenges, molecular biology and genetics of malignant melanoma, as well as the current therapeutic options for patients with this diagnosis.

摘要

几乎每一例晚期皮肤肿瘤年轻患者的死亡都是由黑色素瘤引起的。如今,在现代治疗手段的帮助下,这些患者存活时间更长,甚至能够治愈。晚期黑色素瘤通常预后较差,由于对初始治疗方案缺乏持久反应以及免疫治疗/靶向分子治疗后缺乏随机临床试验,医生们仍然觉得这种疾病难以处理。关于黑素细胞基因图谱的临床前数据以及对参与恶性转化发病机制的分子因素的识别,正在催生出新的治疗靶点。在本文中,我们介绍了恶性黑色素瘤的诊断挑战、分子生物学和遗传学,以及针对该诊断患者的当前治疗选择。

相似文献

1
Pathology and Molecular Biology of Melanoma.
Curr Issues Mol Biol. 2023 Jun 30;45(7):5575-5597. doi: 10.3390/cimb45070352.
2
Melanoma treatment in review.
Immunotargets Ther. 2018 Jun 7;7:35-49. doi: 10.2147/ITT.S134842. eCollection 2018.
3
Biomarkers in melanoma.
Scand J Clin Lab Invest Suppl. 2016;245:S104-12. doi: 10.1080/00365513.2016.1210336. Epub 2016 Jul 28.
4
Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. doi: 10.18553/jmcp.2014.20.4.346.
5
Molecular biology of normal melanocytes and melanoma cells.
J Clin Pathol. 2013 Aug;66(8):644-8. doi: 10.1136/jclinpath-2013-201471. Epub 2013 Mar 23.
6
Update on Metastatic Uveal Melanoma: Progress and Challenges.
BioDrugs. 2016 Jun;30(3):161-72. doi: 10.1007/s40259-016-0167-4.
7
Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Melanoma Res. 2015 Dec;25(6):461-9. doi: 10.1097/CMR.0000000000000200.
8
Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Pathology. 2016 Feb;48(2):113-31. doi: 10.1016/j.pathol.2015.12.007. Epub 2016 Jan 18.
10
Wandering Mucosal Melanoma Presenting as Occult Gastrointestinal Blood Loss Anemia.
Cureus. 2022 Jun 2;14(6):e25614. doi: 10.7759/cureus.25614. eCollection 2022 Jun.

引用本文的文献

1
The Multifaceted Role of the IL-2 Cytokine Family in Melanoma: Mechanisms, Therapeutic Implications, and Immune Modulation.
J Immunol Res. 2025 Jul 2;2025:8890939. doi: 10.1155/jimr/8890939. eCollection 2025.
5
Molecular Susceptibility and Treatment Challenges in Melanoma.
Cells. 2024 Aug 20;13(16):1383. doi: 10.3390/cells13161383.

本文引用的文献

1
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
Expert Opin Biol Ther. 2023 May;23(5):383-388. doi: 10.1080/14712598.2023.2215922. Epub 2023 May 24.
3
TERT Promoter Mutations and Telomerase in Melanoma.
J Oncol. 2022 Jul 19;2022:6300329. doi: 10.1155/2022/6300329. eCollection 2022.
4
Tyrosinase suppresses vasculogenic mimicry in human melanoma cells.
Oncol Lett. 2022 May;23(5):169. doi: 10.3892/ol.2022.13289. Epub 2022 Apr 6.
6
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.
JAMA Dermatol. 2022 May 1;158(5):495-503. doi: 10.1001/jamadermatol.2022.0160.
7
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
Clin Cancer Res. 2022 Jul 15;28(14):3002-3010. doi: 10.1158/1078-0432.CCR-21-3872.
8
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
9
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.
Onco Targets Ther. 2021 Nov 27;14:5345-5352. doi: 10.2147/OTT.S325208. eCollection 2021.
10
Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis.
Front Oncol. 2021 Sep 8;11:737760. doi: 10.3389/fonc.2021.737760. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验